Citi initiates Dianthus Therapeutics coverage with Buy rating

September 4, 2026 5:09 AM

Citi analyst Samantha Semenkow initiated coverage of Dianthus Therapeutics (NASDAQ: DNTH) with a Buy rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found